PT2771329E - Novos compostos di-substituído de 3,4-diamino-3- ciclobuteno-1,2-diona para uso no tratamento de doenças mediadas por quimiocinas - Google Patents
Novos compostos di-substituído de 3,4-diamino-3- ciclobuteno-1,2-diona para uso no tratamento de doenças mediadas por quimiocinas Download PDFInfo
- Publication number
- PT2771329E PT2771329E PT127918258T PT12791825T PT2771329E PT 2771329 E PT2771329 E PT 2771329E PT 127918258 T PT127918258 T PT 127918258T PT 12791825 T PT12791825 T PT 12791825T PT 2771329 E PT2771329 E PT 2771329E
- Authority
- PT
- Portugal
- Prior art keywords
- radical
- methyl
- methylfuran
- group
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552940P | 2011-10-28 | 2011-10-28 | |
| FR1159833A FR2981935B1 (fr) | 2011-10-28 | 2011-10-28 | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2771329E true PT2771329E (pt) | 2016-06-17 |
Family
ID=45809111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT127918258T PT2771329E (pt) | 2011-10-28 | 2012-10-26 | Novos compostos di-substituído de 3,4-diamino-3- ciclobuteno-1,2-diona para uso no tratamento de doenças mediadas por quimiocinas |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9388149B2 (enExample) |
| EP (1) | EP2771329B1 (enExample) |
| JP (1) | JP6068486B2 (enExample) |
| KR (1) | KR20140090168A (enExample) |
| CN (1) | CN103906738B (enExample) |
| AU (1) | AU2012328198A1 (enExample) |
| BR (1) | BR112014009889A2 (enExample) |
| CA (1) | CA2848263A1 (enExample) |
| CY (1) | CY1117705T1 (enExample) |
| DK (1) | DK2771329T3 (enExample) |
| ES (1) | ES2569053T3 (enExample) |
| FR (1) | FR2981935B1 (enExample) |
| HR (1) | HRP20160608T1 (enExample) |
| HU (1) | HUE029128T2 (enExample) |
| IN (1) | IN2014CN02273A (enExample) |
| MX (1) | MX342924B (enExample) |
| PL (1) | PL2771329T3 (enExample) |
| PT (1) | PT2771329E (enExample) |
| RS (1) | RS54775B1 (enExample) |
| RU (1) | RU2014121390A (enExample) |
| SI (1) | SI2771329T1 (enExample) |
| SM (1) | SMT201600151B (enExample) |
| WO (1) | WO2013061004A1 (enExample) |
| ZA (1) | ZA201401678B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029826B1 (ru) | 2013-12-02 | 2018-05-31 | Кемосентрикс, Инк. | Соединения против ccr6 |
| FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| AU2018318075B2 (en) | 2017-08-14 | 2023-04-13 | Allergan, Inc. | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof |
| US11207294B2 (en) | 2018-01-08 | 2021-12-28 | Chemocentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2 |
| WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
| GEP20237476B (en) | 2018-09-21 | 2023-03-27 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors |
| EP4143179B1 (en) | 2020-04-30 | 2025-10-22 | Idorsia Pharmaceuticals Ltd | Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators for the treatment of cancer |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| WO2023072924A1 (en) | 2021-10-26 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| AU2022374959A1 (en) | 2021-10-28 | 2024-06-06 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| KR20260005351A (ko) * | 2023-04-28 | 2026-01-09 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | Ccr6 길항제로서의 화합물, 이의 약학 조성물 및 용도 |
| CN121693497A (zh) * | 2023-11-03 | 2026-03-17 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6652737B2 (en) * | 2000-07-21 | 2003-11-25 | Exxonmobil Research And Engineering Company | Production of naphtha and light olefins |
| RU2344123C9 (ru) * | 2001-04-16 | 2009-05-20 | Шеринг Корпорейшн | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора |
| US8183281B2 (en) * | 2007-06-06 | 2012-05-22 | Novartis Ag | CXC-chemokine receptor ligands |
| UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| KR200444641Y1 (ko) * | 2008-12-03 | 2009-05-27 | 강민수 | 헤드작동형 다기능 스패너 |
| WO2010063802A1 (en) * | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010131146A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
-
2011
- 2011-10-28 FR FR1159833A patent/FR2981935B1/fr not_active Expired - Fee Related
-
2012
- 2012-10-26 US US14/354,033 patent/US9388149B2/en not_active Expired - Fee Related
- 2012-10-26 CN CN201280052911.8A patent/CN103906738B/zh not_active Expired - Fee Related
- 2012-10-26 RU RU2014121390/04A patent/RU2014121390A/ru not_active Application Discontinuation
- 2012-10-26 HR HRP20160608TT patent/HRP20160608T1/hr unknown
- 2012-10-26 DK DK12791825.8T patent/DK2771329T3/en active
- 2012-10-26 IN IN2273CHN2014 patent/IN2014CN02273A/en unknown
- 2012-10-26 ES ES12791825.8T patent/ES2569053T3/es active Active
- 2012-10-26 MX MX2014003958A patent/MX342924B/es active IP Right Grant
- 2012-10-26 HU HUE12791825A patent/HUE029128T2/en unknown
- 2012-10-26 CA CA2848263A patent/CA2848263A1/fr not_active Abandoned
- 2012-10-26 AU AU2012328198A patent/AU2012328198A1/en not_active Abandoned
- 2012-10-26 KR KR1020147011443A patent/KR20140090168A/ko not_active Withdrawn
- 2012-10-26 RS RS20160367A patent/RS54775B1/sr unknown
- 2012-10-26 JP JP2014537704A patent/JP6068486B2/ja not_active Expired - Fee Related
- 2012-10-26 PT PT127918258T patent/PT2771329E/pt unknown
- 2012-10-26 EP EP12791825.8A patent/EP2771329B1/fr active Active
- 2012-10-26 WO PCT/FR2012/052478 patent/WO2013061004A1/fr not_active Ceased
- 2012-10-26 BR BR112014009889A patent/BR112014009889A2/pt not_active IP Right Cessation
- 2012-10-26 SI SI201230577A patent/SI2771329T1/sl unknown
- 2012-10-26 PL PL12791825.8T patent/PL2771329T3/pl unknown
-
2014
- 2014-03-06 ZA ZA2014/01678A patent/ZA201401678B/en unknown
-
2016
- 2016-05-31 SM SM201600151T patent/SMT201600151B/it unknown
- 2016-06-02 CY CY20161100489T patent/CY1117705T1/el unknown
- 2016-06-07 US US15/175,363 patent/US9580412B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2981935B1 (fr) | 2015-08-07 |
| CN103906738B (zh) | 2016-09-07 |
| SI2771329T1 (sl) | 2016-07-29 |
| RS54775B1 (sr) | 2016-10-31 |
| HRP20160608T1 (hr) | 2016-07-01 |
| CN103906738A (zh) | 2014-07-02 |
| US20160362403A1 (en) | 2016-12-15 |
| CY1117705T1 (el) | 2017-05-17 |
| PL2771329T3 (pl) | 2016-09-30 |
| IN2014CN02273A (enExample) | 2015-06-19 |
| FR2981935A1 (fr) | 2013-05-03 |
| EP2771329B1 (fr) | 2016-03-16 |
| US9580412B2 (en) | 2017-02-28 |
| WO2013061004A8 (fr) | 2014-04-17 |
| MX342924B (es) | 2016-10-19 |
| ZA201401678B (en) | 2015-04-29 |
| RU2014121390A (ru) | 2015-12-10 |
| HUE029128T2 (en) | 2017-02-28 |
| KR20140090168A (ko) | 2014-07-16 |
| SMT201600151B (it) | 2016-07-01 |
| US20140296254A1 (en) | 2014-10-02 |
| US9388149B2 (en) | 2016-07-12 |
| JP6068486B2 (ja) | 2017-01-25 |
| AU2012328198A1 (en) | 2014-04-03 |
| MX2014003958A (es) | 2014-08-27 |
| DK2771329T3 (en) | 2016-06-06 |
| WO2013061004A1 (fr) | 2013-05-02 |
| ES2569053T3 (es) | 2016-05-06 |
| EP2771329A1 (fr) | 2014-09-03 |
| JP2014530894A (ja) | 2014-11-20 |
| BR112014009889A2 (pt) | 2017-04-25 |
| CA2848263A1 (fr) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6068486B2 (ja) | ケモカイン媒介性疾患の処置に使用するための新規二置換３，４−ジアミノ−３−シクロブテン−１，２−ジオン化合物 | |
| US9090596B2 (en) | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | |
| US9415039B2 (en) | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
| KR101991326B1 (ko) | 오피오이드 수용체 리간드와 그 용도 및 제조방법 | |
| KR20160052766A (ko) | 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드 | |
| RU2469033C2 (ru) | СОЕДИНЕНИЯ ДИБЕНЗО[b,f][1,4]ОКСАЗАПИНА | |
| JP2025510348A (ja) | Ｐ２ｘ３阻害剤化合物及びその塩、結晶多形並びに使用 | |
| Bai et al. | Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives | |
| CN118234716A (zh) | 艾地苯醌衍生物及其在治疗植物中的用途 | |
| CN101735207B (zh) | 含γ亚基丁烯内酯基团的地洛他定衍生物及其合成方法 | |
| WO2025223427A1 (zh) | 一种五元杂环类化合物、药物组合物及其应用 | |
| WO2025223430A1 (zh) | 一种五元杂环类化合物、药物组合物及其应用 |